Avalo Therapeutics (AVTX) Leases (2019 - 2025)
Avalo Therapeutics (AVTX) has disclosed Leases for 7 consecutive years, with $402000.0 as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Leases fell 64.71% year-over-year to $402000.0, compared with a TTM value of $402000.0 through Sep 2025, down 64.71%, and an annual FY2024 reading of $741000.0, down 44.24% over the prior year.
- Leases was $402000.0 for Q3 2025 at Avalo Therapeutics, down from $487000.0 in the prior quarter.
- Across five years, Leases topped out at $2.0 million in Q4 2021 and bottomed at $402000.0 in Q3 2025.
- Average Leases over 5 years is $1.2 million, with a median of $1.3 million recorded in 2024.
- The sharpest move saw Leases skyrocketed 159.74% in 2022, then plummeted 64.71% in 2025.
- Year by year, Leases stood at $2.0 million in 2021, then fell by 12.54% to $1.8 million in 2022, then decreased by 24.06% to $1.3 million in 2023, then plummeted by 44.24% to $741000.0 in 2024, then tumbled by 45.75% to $402000.0 in 2025.
- Business Quant data shows Leases for AVTX at $402000.0 in Q3 2025, $487000.0 in Q2 2025, and $615000.0 in Q1 2025.